Selected article for: "CAI codon adaptation index and codon adaptation index"
Author: Saba Ismail; Sajjad Ahmad; Syed Sikander Azam
Title: Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine
  • Document date: 2020_4_12
    • ID: 3jmo35jc_2
    Snippet: The study presented, herein, is an attempt to get insights about antigenic determinants of SARS-CoV-2 spike glycoprotein and highlight all antigenic epitopes [31] of the spike that can be used specifically for the design of a multi-epitope peptide vaccine construct (MEPVC) [32] to counter COVID-19 infections. The epitopes predicted by immunoinformatics techniques were fused together as well as to β-defensin adjuvant [33, 34] to boost the antibod.....
    Document: The study presented, herein, is an attempt to get insights about antigenic determinants of SARS-CoV-2 spike glycoprotein and highlight all antigenic epitopes [31] of the spike that can be used specifically for the design of a multi-epitope peptide vaccine construct (MEPVC) [32] to counter COVID-19 infections. The epitopes predicted by immunoinformatics techniques were fused together as well as to β-defensin adjuvant [33, 34] to boost the antibody production and long- 5 MEPVC sequence was translated reversibly for optimization of codon usage according to Escherichia coli K12 expression system in order to get high expression rate [56] . For this, Java Codon Adaptation Tool (JCat) [57] was used and expression of the cloned MEPVC was assessed by GC % and codon adaptation index (CAI) value. SnapGene (https://www.snapgene.com/) was used to clone the optimized MEPVC cDNA into pET-28a (+) expression vector.

    Search related documents:
    Co phrase search for related documents
    • expression vector and β defensin adjuvant: 1
    • expression vector and peptide vaccine: 1, 2
    • expression vector and study present: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • β defensin adjuvant and study present: 1, 2, 3
    • β defensin and study present: 1, 2, 3, 4, 5, 6, 7, 8
    • infection counter and study present: 1, 2
    • MEPVC multi epitope peptide vaccine construct and multi epitope peptide vaccine: 1, 2
    • MEPVC multi epitope peptide vaccine construct and multi epitope peptide vaccine construct: 1, 2
    • MEPVC multi epitope peptide vaccine construct and peptide vaccine: 1, 2
    • multi epitope peptide vaccine and peptide vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • multi epitope peptide vaccine and study present: 1, 2, 3, 4, 5, 6
    • multi epitope peptide vaccine construct and peptide vaccine: 1, 2
    • peptide vaccine and study present: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32